Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Shares of Regeneron Pharmaceuticals Inc. rose 4.94% to $517.60 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.09% to 6,005.88 ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...